Diagnostic and follow-up @entity1712 is not predictive of outcome in XXXX .

@entity1712 @entity1 @entity5 @entity1184 @entity3052 @entity236
BACKGROUND: Peripheral blood @entity1712 (PBE) and @entity236 ( @entity236 ) are associated with various @entity5 . @entity1712 is frequently paraclonal (because of cytokines and not part of the malignant clone), but in some cases of @entity3052 ( @entity3052 ), it may also be clonal. METHODS: We retrospectively evaluated 80 @entity3052 @entity1 treated from June 2004 to December 2008 at our @entity5 center for PBE and @entity236 at diagnosis and postinduction. RESULTS: At diagnosis, PBE was present in 18.8% @entity1 whereas at postinduction it was observed in 7.7% @entity1 . No @entity1 had abnormal eosinophils. At diagnosis, PBE correlated with the absence of gum @entity1184 whereas @entity236 correlated with the French-American-British-M2 subtype and absence of gum @entity1184 . PBE/ @entity236 did not have a significant correlation with event-free survival. After completion of therapy, on follow-up up to 2 years every 3 months, one-third of the @entity1 had @entity1712 ; however, it did not correlate with disease-free survival. CONCLUSIONS: This is the first study to evaluate the impact of @entity1712 at presentation, postinduction, and on follow-up with outcome in @entity3052 . Although @entity1712 was observed in one-fifth of the @entity1 at diagnosis and in one-third of the @entity1 on follow-up, it seems to be reactive in nature with no impact on outcome and thus it should not be a cause of alarm.
